Compare IQV & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | NTRA |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6B | 28.0B |
| IPO Year | 2013 | 2015 |
| Metric | IQV | NTRA |
|---|---|---|
| Price | $156.40 | $206.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | $227.13 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.67 | 0.65 |
| EPS | ★ 7.84 | N/A |
| Revenue | ★ $9,739,000,000.00 | $210,939,000.00 |
| Revenue This Year | $6.77 | $18.08 |
| Revenue Next Year | $5.89 | $19.65 |
| P/E Ratio | $20.30 | ★ N/A |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $134.65 | $131.81 |
| 52 Week High | $247.05 | $256.36 |
| Indicator | IQV | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 52.52 |
| Support Level | N/A | $185.17 |
| Resistance Level | $193.26 | $220.33 |
| Average True Range (ATR) | 5.68 | 9.09 |
| MACD | -1.59 | -0.01 |
| Stochastic Oscillator | 7.16 | 57.83 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.